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Epigenetics in cancer 
 
In human cancers, aberrant epigenomics are known to contribute to various phases of 
neoplastic development including initiation, promotion, invasion and chemotherapy 
resistance. Epigenetics refers to the study of heritable changes in gene expression that 
occur without alterations in DNA sequence. Histone modifications and DNA methylation 
are the key processes responsible for epigenetic regulation. Post-translational 
modifications to histone tails influence chromatin structure which plays an important role 
in the control of the transcriptional status of genes in a particular locus 1,2. DNA 
methylation exerts critical effects on gene-expression regulation in normal cells, and 
alterations on the normal methylation patterns characte ize, and likely contribute, to 
cancer development and progression. Reversible methylation of cytosines takes place 
within CG dinucleotides clustered at the promoter region of around 60% of all human 
genes and in repetitive sequences interspersed along the genome. It constitutes an 
essential mechanism that is present in normal “healt y” cells. As a regulatory system, this 
process contributes to the maintenance of genome integr ty by keeping endoparasitic 
sequences inactive through heavy methylation; it maintains tissue-specific expression 
patterns and defines genomic imprinting.  
In terms of DNA methylation, cancer cells show genome-wide hypomethylation and site-
specific CpG island promoter hypermethylation 3,4. Loss of DNA methylation at CpG 
dinucleotides was the first epigenetic abnormality to be identified in cancer cells more 
than 25 years ago 5. It was recognized that a widespread DNA hypometilation may convey 
diverse effects upon epithelial cells, including an increase in genome instability due to the 
altered chromatin structure and the activation of transposable elements like LINEs and 
SINEs 6. In addition, gene-specific hypomethylation has been identified as a way to 
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activate proto-oncogenes, such as MAGE in melanomas and CAGE in stomach and liver 
cancers among others 7,8. Furthermore, hypomethylation at specific promoters can activate 
the normally methylated parental allele inducing loss of imprinting (LOI). For example, 
LOI affecting IGF2 is reported as a common event in cancers of colon and of other sites 
9,10. 
Aberrant methylation of gene promoters can mimic genetic mutation or deletion by 
abolishing the expression of genes involved in all cellular pathways, and it is of particular 
significance in the context of inactivation of tumour suppressor genes, thus allowing 
malignant progression 11,12. Methylation process takes place at the 5’ position of cytosine 
(m5C, 5-methylcytosine) and is catalyzed by the enzymes of DNA methyltransferase 
family (DNMTs). DNA methylation can inhibit gene expression directly, preventing the 
binding of transcription factors, and indirectly, by recruiting methyl-CpG-binding domain 
proteins (MBDs). These proteins in turn recruit histone-modifying and chromatin-
remodeling complexes at methylated sites 13 (figure 1). 
 
Figure 1. Silencing of genes by methylation. DNA methylation can silence genes by either direct 
or indirect mechanisms. An active gene, shown to the left, is unmethylated. The direct mechanism 




is shown in the top right panel. Methylation of a CG residing in the recognition site for a 
transcription factor inhibits the binding of a critical transcription factor to the gene, resulting in 
blocking of transcription. In the second mechanism, hown at the bottom right, methylated CGs 
attract DNA binding factors which in turn recruit co-repressors, resulting in a change in chromatin 
structure to an inactive configuration. (Modified from Szyf et al. 14). 
 
Epigenetics and genetics interplay has recently becom  to emerge 15. Mutations and 
deletions or even polymorphic variations occurring i  just mentioned proteins belonging 
to the epigenetic machinery has been documented in several studies (reviewed in 16). On 
the other hand, deregulated epigenetic mechanisms may initiate genetic instability 
resulting in the acquisition of inactivating mutations in tumour suppressor genes (TSGs) 
and activating mutations in oncogenes. Furthermore, m5C is highly mutable by 
deamination, resulting in transitional mutations (i.e. C to T).  
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Epigenetics in colorectal cancers 
 
Colon cancer has become a paradigm in epigenetic resea ch. In the last 20 years, many 
works have reported a great number of genes which are targets of aberrant methylation 
process in colon disease.  
DNA hypermethylation-induced gene silencing is a common event that affect TSGs 
promoter and serves as an alternative mechanism to genetic mutation for the loss of tumor 
suppressor functions 11,12. As reported in table 1, these genes are involved in many cellular 
processes, such as DNA repair, cell cycle control, Ras signalling, apoptosis, metastasis, 
vitamine response and p53 network among others.  
Although the mechanisms that underlay aberrant DNA methylation in cancer cells remain to 
be elucidated, current evidence suggests that it may be an early and possibly even an 
initiating event in the development of colorectal cn er (CRC). 
 
 
Table 1. Frequent targets of aberrant methylation processes in tumorigenesis 
 




It is a regulator of the dynamic cellular 
adhesion–deadhesion processes, and its 
inactivation contributes to the 
dissemination of cancer cells 
Aberrant crypt foci 
and adenomas 
CRBP1 
Retinol binding protein1 
Encodes a carrier protein involved in the 
transport of retinol (vitamin A alcohol).  
Methylation may contribute to the loss of 





Its  silencing contributes to the inactivation 
of gamma-interferon induced programmed 
cell death 
Hypermethylation 
was already observed 
in colon mucosa 
adjacent to carcinoma 
IGF2 
Insulin-like growth factor 
Loss of imprinting at this locus is a risk 














mucosa of cancer 
patients 
WIF1 
Wnt inhibitory factor-1 
It  contributes to the aberrant activation of 
Wnt signaling 
Proposed as a 
valuable biomarker in 
plasma for early 
detection of CRC 
RASGRF2 
Ras guanine nucleotide-
releasing factor 2 
Implicated in Ras-mediated signaling and 
development 
Aberrant crypt foci 
and adenomas 
APC 
Adenomatous polyposis coli 
Antagonist of the Wnt signaling pathway, 
it’s involved in aberrant cell migration, 






Involved in inflammation and mitogenesis, 




GATA binding protein 4 
Suppresses colony formation, proliferation, 
migration, invasion, and anchorage-
independent growth of colorectal cancer 
cells 
Aberrant crypt foci 
and adenomas 
GATA5 
GATA binding protein 5 
Suppresses colony formation, proliferation, 
migration, invasion, and anchorage-
independent growth of colorectal cancer 
cells 
Aberrant crypt foci 
and adenomas 
HIC 
Hypermethylated in cancer 
Modulates the transcriptional stimulation of 
genes regulated by Wnt/beta-catenin 
signaling. Inactivation in cancer leads to 
abnormal cell proliferation at early stages 
Adenomas 
hMLH1 
mutL homolog 1 






Tumour suppressor gene, stabilizer of the 
tumour suppressor protein p53 and 




kinase inhibitor 2A 
Tumour suppressor gene, negative regulator 
of cell growth and proliferation in the G1 
phase of the cell cycle, and is an important 
regulator of the angiogenic switch 
Adenomas 
RARb   
Retinoic acid receptor 
It mediates the 




Ras association domain 
family member 1 
It inhibits the accumulation of cyclin D1, 
and thus induces cell cycle arrest. 
Methylation of this gene is an early event in 
CRC 
Adenomas 
Modified from Carmona et al.17 
 
INTRODUCTION 8 
In fact, several studies identified aberrant promoter methylation in early precursor lesions, 
such as aberrant crypt foci (ACF) 18, adenomas 19 and even in tumour-adjacent normal-
appearing mucosa 20. Many reports now are being published about the changes in the 
methylation status of normal background mucosa during the development of colorectal 
neoplasia. The “field effect” model suggests that precancerous cells proximal to the 
cancer cells harbour some of the genetic alterations that are present in fully developed 
cancer. For example, Shen et al. 21 detected methylation of the promoter region of MGMT 
in the normal mucosa adjacent to colon tumor tissue in 22 (50%) out of 44 patients whose 
tumors exhibited MGMT promoter methylation but in only three (6%) out of 51 patients 
without it. These results indicate that some CRC may arise from a field effect defined by 
epigenetic alteration of MGMT. 
Many attempts have been made to identify the methyla ion patterns appearing at the 
various stages of colorectal cancer progression, although the different techniques 
employed, the uneven criteria for selecting samples and the biased validation methods 
have yielded little consensus about the number of loci defining each step of cancer 
development. In 1999, Toyota and co-workers identified a series of methylation markers 
whose status defined the CpG island methylator phenotype (CIMP) 22. This proposal 
emerged as a new pathway for colorectal tumourigenesis, in addition to the classic 
mutator or chromosomal instable (CIN) and microsatellite instable (MSI) categories, 
standing for a subset of sporadic colorectal tumours bearing excessive cancer-specific 
promoter hypermethylation. This molecular subgroup f tumours claimed to group up to 
75% of sporadic CRC with MSI, and was initially characterized for exhibiting concordant 
tumour-specific promoter hypermethylation in a series of markers (CDKN2A, MLH1, 
THBS1, MINT1, MINT2, MINT31). Later, Weisenberger et al. established another panel to 
support the CIMP as a distinct molecular trait of CRC, identifying a new diagnostic panel 
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of markers (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) 23. Subsequently, in two 
large prospective cohort studies, Ogino et al. validated the usefulness of eight methylation 
markers including markers established by Weisenberger et al. (CACNA1G, IGF2, 
NEUROG1, RUNX3, SOCS1, CDKN2A/p16, CRABP1, and MLH1) in CIMP classification 
24. 
However, some authors did not observe the bimodal distribution of methylation 
frequencies. This controversy might be due to the inclusion of MSS and/or MSI-H in 
these studies or due to tumor heterogeneity 25. In fact not all CpG islands are methylated 
in a similar manner in CRC and thus the choice of markers can affect the features of 
CIMP 26,27.  
However, later, considerable research activity has been performed regarding markers able 
to accurately identify CIMP tumors.  Among others, a comprehensive analysis of CIMP 
has been performed in CRC using a large population-based sample (904 tumors) 28.
Utilizing an expanded set of methylation markers (16 CpG islands), this study revealed 
that CIMP+ tumors are independently associated withpoor differentiation, MSI-H and 
BRAF mutation. This group of tumors is also inversely correlated with LINE-1 
hypomethylation and β- catenin (CTNNB1) activation. In a later study 29, the CIMP+ 
tumors were further subdivided into two molecularly distinct subclasses by genetic 
characteristics. By an integrated genetic and epigenetic analysis with 27 promoter-
associated CpG islands, Shen et al. 29 found that CIMP+ cases fitted into two subgroups 
(CIMP1 and CIMP2) and that they corresponded to very distinct genetic profiles. CIMP1 
are characterized by a high frequency of MSI and BRAF mutations (more than 50%) with 
few KRAS and TP53 mutations. CIMP2 is associated with a high frequency of KRAS 
mutations (92%), but MSI and BRAF mutations occurred rarely with a low rate of TP53 
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mutation. Conversely, CIMP− cases that showed low or less methylation for all genes 
examined have a high rate of TP53 mutations (71%) with lower rates of MSI (12%) or  
 
 
Figure 2. Multiple pathways to progression of colorectal tumors. Three distinct parallel 
pathways (CIN, CIMP+/MSI, and CIMP+/MSS) for the prog ession of CRC from normal colon 
mucosa have been recently proposed by Issa. Modified from Kim et al.30 
 
mutations of BRAF (2%) or KRAS (33%). 
Even though the CIMP approach to the classification f CRC has accelerated 
understanding of CIMP in colon carcinogenesis, the absence of a consensus panel 
defining the CIMP groups makes the comparison of the literature difficult. In addition, 
inclusion of genes showing age-related methylation or genes whose methylation is 
associated with better prognosis might lead to an underestimation of true frequency or 
prognostic value of CIMP 31. For example, using different marker panels, CIMP+ was 
found to correlate with a worse prognosis in a repot 32,33 but not in another study 34.  
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The concordant methylation of multiple genes has been observed in other types of cancer, 
suggesting that CIMP is a common occurrence in human neoplasms. However, it is still 
not clear whether the CIMP molecular phenotype represents a biologically distinct group 
of cancer, whether it is only observed in selected groups showing different degrees of 
methylation at particular loci, or whether it is deriv d from a group of tumors that are part 
of a normal distribution with regard to aberrant DNA methylation. It is also controversial 
whether this “epigenetic instability” is integral to tumor initiation and progression.  
Finally, CpG island methylation is an early and widespread phenomenon in colorectal 
carcinogenesis and a lot of studies have shown evidence for a CIMP-phenotype also in 
stable (MSS) CRCs. Moreover, some authors 35-37 found a percentage of CIMP+ 
phenotype also among poorly differentiated neuroendcrine carcinomas (NECs) of colon 
and rectum, which are rare and highly malignant cancers that typically harbour high 
chromosomal instability 38,39. However, to date there is little information about the 
incidence of the CIMP phenotype and the specific epigenetic profiles in NECs, mainly 
due to the smallness of the series analyzed. 
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Methods and strategies to investigate promoter methylation 
 
Many different strategies are available for assessing the epigenetic patterns of normal and 
cancer cells. So far, most studies addressing aberrant methylation in colorectal and other 
cancers have focused on genes already known to be involved in cancer pathogenesis, 
especially those for which no genomic mutation had been identified 40. Using the 
candidate-gene approach, a high number of genes inactivated by promoter 
hypermethylation in a given tumour has been recognized 17,40. On the other hand, some 
authors opted for a genome-wide manner to consider DNA methylation events (i.e., by 
studying a limited number of genomic sites that are representative of the genome).  The 
first reports relied on restriction enzyme-based methods suitable for comparing large 
series of samples and the simultaneous identification of hypomethylation and 
hypermethylation events (reviewed in Carmona et al.17). Techniques such as restriction 
landmark genomic scanning (RLGS), which was the first large-scale method for 
investigating methylation and differential methylation hybridisation (DMH), which was 
the first array method to be optimized for identifying novel methylated loci in cancer, are 
among the first examples of large-scale epigenomic techniques 41. Nevertheless, these 
ingenious approaches suffer many technical limitations, including first of all laborious and 
time-consuming protocols and outputs difficult to elaborate. However, despite some  
pitfalls, studies based on these techniques succeeded in identifying a surfeit of abnormally 
methylated loci in cancer, and provided a picture of particular CpG methylation patterns 
shared by many tumour types and of markers exhibiting d stinct tumour-type specificity. 
Later, genetic unmasking strategies opened up a new li  of investigation in the search for 
hypermethylated loci. Specifically, the disruption of the two major DNA 
methyltransferases (DNMT1 and DNMT3b) in the colorectal cancer cell line HCT-116 42
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provided a useful tool for identifying differentially methylated loci on a global genomic 
scale, by comparing the methylation profile of the double knock-out (DKO) with the 
unmodified HCT-116 cell lines. Other methods have exploited the plasticity of epigenetic 
modifications by using pharmacological agents such as 5-aza-2-deoxycytidine (5-aza), 
which is widely employed as a DNA methylation inhibitor to induce gene expression by 
covalent trapping of DNMT, or histone deacetylase inhibitors, such as trichostatin A 
(TSA). Nevertheless, it is important to note that due to the pleiotropic effects produced by 
these epigenetic drugs, many genes not directly affected by aberrant methylation – or not 
even epigenetically regulated – were transcriptionally over-activated. This leads to quite a 
high frequency of false-positive results. 
The advent of the bisulphite treatment of DNA, which converts cytosine residues to uracil, 
but leaves 5-methylcytosine residues unaffected, was a fundamental contribution to cancer 
epigenetics research 43,44. The implementation of this technique in conjunction with PCR 
amplification, for example methylation-specific PCR (MSP) 45, allows the sensitive 
examination of DNA methylation of any sequence, andrequires only very small amounts 
of material. Also, the promoter CpG island hypermethylation in different human cancers 
was comprehensively analyzed using bisulphite sequencing 46, which, to date, has been 
considered the gold standard technique for directly studying DNA methylation and for 
validating results obtained using other approaches. Moreover, pyrosequencing method 
offers, in addition, a quantitative approach to detect different levels of methylation 26. 
These techniques are employed also at a clinical leve . MSP, for example, and Methylight, 
developed as the quantitative version of the MSP technique 47, are being implemented to 
conduct routine diagnostic tests, such as the detection of MGMT methylated promoter for 
patient stratification in the therapy of glioblastoma multiforme 48. Moreover, traditional 
PCR-based techniques are now complemented by several new PCR-based methods for 
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detecting DNA methylation that display increased analytical sensitivity and provide 
quantitative information. For instance, methylation sensitive melting-curve analysis (MS-
MCA) takes advantage of the differential resistance of DNA to melting, depending on the 
relative GC content. A melting analysis performed straight-on after the amplification 
differentiates the products based on their sequence as two different temperature peaks 
should be noticed 49. An improvement of this technique, also based on melting analysis of 
PCR amplicons, is the high-resolution melting-curve analysis (MS-HRM) which is a more 
sensitive approach 50. 
All these methods mentioned above are currently used in a candidate-gene strategy, 
performing a single-gene analysis at time and taking advantage from bisulfite-DNA 
treatment, known to be a time-consuming process. Furthermore, some of them (for 
example Methylight and Pyrosequencing) are quite expensive and need an accurate 
optimization before use. Methylation-Specific Multip e Ligation-dependent Probe 
Amplification (MS-MLPA) is a fast new method that detects methylation status of 
cytosine exploiting methylation-sensitive enzyme thus avoiding bisulfite conversion. It 
allows the screening of multiple genes at time by a simultaneous amplification of 20-30 










Methylation-Specific Multiple Ligation-dependent Probe Amplification (MS-MLPA) 
 
Over the years, the interpretation of studies investigating CIMP in CRC has been 
complicated by the use of several different methods, gene panels, and criteria for defining 
this phenotype 11,17. Most current methods involve single-gene analysis performed with 
labour intensive approaches. By contrast, high throughput methylation approaches are not 
suitable in clinical practice because they are expensiv  and generally not applicable to 
DNA from FFPE tissues 17,30. Methylation-Specific Multiple Ligation-dependent Probe 
Amplification (MS-MLPA) is a fast new inexpensive method that detects methylation in a 
large set of genes simultaneously using only small amounts of DNA from FFPE tissues. 
This technique uses multiple probe sets each consisting of two oligonucleotides, both 
containing a sequence-specific region used for hybridization to the genomic DNA, tagged 
with common tails complementary to a universal primer set (Figure 3). One of the two 
oligonucleotides additionally contains a stuffer sequ nce of a characteristic length, 
allowing separation of the individual loci analyzed. In practice, after over-night 
hybridisation, the sample is divided into two aliquots. In one part of the sample, 
adjacently hybridized probes are joint through ligation, whereas for the other half of the 
sample, ligation is combined with a methylation sensitive restriction enzyme HhaI 
(recognition site GCGC) that digests the unmethylated fragments. Both ligation and 
ligation-digestion probe sets are then amplified by polymerase chain reaction (PCR) and 
analyzed by capillary electrophoresis. By comparison of the electropherogram of ligated 
sample with the one of ligation-digestion sample, the amount of methylation can be 
calculated as a ratio value for each probe. 
To date, the number of studies that employed this technique is reported in literature to be 
about sixty overall. Since this method has been published for the first time in 2005 51  
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Figure 3. Diagram of the steps of MS-MLPA procedure. The MS-MLPA procedure can be 
divided in five steps: 1. DNA denaturation and hybridisation of MLPA probes; 2. ligation and 




many works have been described especially in the res a ch field of  imprinting disorders 
or hematologic diseases. In recent years the clinica  utility of this method is strongly 
emerging as a promising tool to rapidly screen the routinely standard-processed tumors or 
the archival tissues in retrospective studies 52-54. However, the translational application of 







The aims of our work were to investigate the methylation status of 34 tumor suppressor 
genes in a series of 104 formalin-fixed and paraffin-embedded specimens, including 83 
exocrine adenocarcinomas and 21 neuroendocrine cancrs.  
First we evaluated the feasibility and the effectiveness of the employment of MS-MLPA 
to rapidly screen an archival series of FFPE tissue. We analyzed the accuracy of this 
method by assessing sensitivity and specificity through ROC analysis. 
Clinico-pathological and molecular characteristics were collected for all cases and used to 
correlate methylation profiles in subsets of clinically and biologically different tumours. 
Furthermore, we studied samples of colorectal mucosa from 13 CRC patients and from 12 
patients with negative history for colorectal cancer. In particular we evaluated whether: 
 gene methylation patterns, if present in normal-appe ring mucosa of CRC patients, 
showed cancer-specific signature or were similar to those of  colonic mucosa of non-
CRC patients; 
 methylator phenotype (CIMP) was a peculiarity of unstable tumours or if other subsets 
of cancer shared this phenotype; 
  distinct patterns of methylated genes could characte ize exocrine versus 
neuroendocrine tumours; 
 CIMP phenotype or single gene status could serve as prognostic marker.




MATERIALS AND METHODS 
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Patients and samples 
 
This study was performed on 104 tumor samples, including 83 sporadic CRCs and 21 
NECs. The clinico-pathological and molecular profiles of all 83 exocrine cancers were 
previously examined and published 55. The NECs consisted of a series of archived FFPE 
tissue samples from 21 patients who underwent curative surgical resection between 1989 
and 2009 at the Ospedale di Circolo, Varese. The inclusion criterion for these cases was 
the availability of tumor tissue for molecular analysis. All samples were histologically 
reviewed by two independent pathologists according to the WHO classification of tumors 
of the digestive system 56,57 and the TNM staging system 58,59. 
Outcome data were collected by consulting clinical records and/or the Tumor Registry of 
the Lombardy region (Italy) and were available for all but six patients (94.2% of patients). 
Thirty-three patients (33.7%) died of disease while fifty-eight patients (59.2%) were alive 
(median follow-up time of 16 months and 75 months, re pectively). Seven patients (7.1%) 
were excluded from the survival analysis because they died within the first 30 days after 
tumor resection. BRAF and KRAS mutation tests, microsatellite instability (MSI-H) and 
loss of heterozygosity (LOH) studies on chromosomes 5q, 17p and 18q were previously 
performed 55. Molecular and clinico-pathological informations of all 104 tumors are 
summarized in table 2. 
Twenty-five samples of normal-looking colonic mucosa from 25 patients were also 
included in this study. The selection of these 25 normal samples was carried out in order 
to represent all colorectal segments; the median age of the patients was 70 years, without 
significant differences between the two groups. Thirteen of these samples were derived 
from normal tissue at the resection margins of 13 patients with CRCs included in this 
study. The remaining normal specimens were obtained from 12 individuals who had  
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Gender     
Male 44 53% 13 62% 
Female 39 47% 8 38% 
Age      
Median (minimum-maximum) 68 (41-91) 69.5 (44-85) 
Site     
Right 36 43% 10 48% 
Left 47 57% 11 52% 
Histotype     
Glandular 65 78% -  
Mucinous 13 16% -  
Diffuse 1 1% -  
Signet-ring cell 3 4% -  
Grade of differentiation     
G1-G2 66 80% 0 0% 
G3 17 20% 21 100% 
TNM stage     
Stage I-II 38 49% 4 20% 
Stage III-IV 39 51% 16 80% 
Microscopic growth     
Expansive 19 23% 0 0% 
Infiltrative 64 77% 9 100% 
Neuroinvasion     
Absent 60 72% 7 44% 
Present 23 28% 9 56% 
Angio-lymphoinvasion     
Absent 55 66% 4 24% 
Present 28 34% 13 76% 
Histological heterogeneity     
Absent 50 60 % 21 100 % 
Present 33 40 % 0  0 % 
Tumor infiltrating lymphocytes     
Absent 20 24% 11 92% 
Present 63 76% 1 8% 
Microsatellite instability status     
MSI-H 19 23% 2 10% 
MSS 64 77% 19 90% 
Loss of Heterozygosity (5q, 17p, 18q)     
Absent 28 36% 1 7% 
Present 50 64% 13 93% 
BRAF mutation     
Absent 72 87% 19 95% 
Present 11 13% 1 5% 
KRAS mutation     
Absent 65 81% 14 70% 
Present 15 19% 6 30% 
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undergone surgery for ischemic colorectal disease or for diverticulitis without a personal 
history of CRC. 
 
DNA extraction and evaluation of amplifiability 
 
DNA samples were obtained from formalin fixed and paraffin embedded tissues using 
representative 8-µm sections. Three sections of every specimen were treated twice with 
xylene, and then washed twice with ethanol. DNA wasextracted using a QIAamp® DNA 
FFPE Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
Neoplastic areas were manually microdissected for DNA extraction and contained at least 
70% of tumor cells, to minimize contamination by normal cell. Each DNA sample was 
evaluated for integrity and amplifiability by BIOMED-2 multiplex PCR 60 in order to 
correlate DNA fragmentation with MS-MLPA reproducibility. Briefly, as illustrated in 
figure 4, five pairs of control gene PCR primers were used to amplify products of exactly 
100, 200, 300, 400 and 600 bp from the following four target genes: TBXAS1 (exon 9), 
RAG1 (exon 2), PLZF (exon 1), AF4 (exon 11), AF4 (exon 3) 60. DNA fragmentation and 
MS-MLPA reproducibility were correlated. 
 
Figure 4. Control gene PCR 
for the assessment of 
amplifiability and integrity  
of DNA samples. a) 
Schematic representation of 
control genes exons and 
primer sets. b) PCR products 
separated in a 3% agarose gel. 
Modified from van Dongen et 
al.60 
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Methylation-specific multiplex ligation-dependent probe amplification 
 
The SALSA MS-MLPA ME001 Tumor suppressor-1 Kit and SALSA MS-MLPA ME002 
Tumor suppressor-2 Kit (MRC-Holland, Amsterdam, The N therlands) were used to 
perform promoter methylation analysis on all 104 tumors and 25 normal samples 
previously mentioned. 
Each kit used in our study contains 27 MS-MLPA probes that detect the methylation 
status of promoter regions of 24 tumor suppressor genes. All these genes are frequently 
silenced by methylation in tumors of different site, but are unmethylated in blood-derived 
DNA of healthy individuals. Using both kits, we examined a total of 34 different tumor 
suppressor genes due to a partial overlapping between the two probe-mixes. Seventeen 
genes were addressed by two probes that recognized d ff rent HhaI restriction sites in 
their promoter regions. All probes, target genes, sequence accession number and 
amplicone size are reported in table 3 with the exception of two genes, CDKN2B and 
MSH6, that were excluded from further analyses after ch cking the specificity of the test. 
Additional information, such as probe sequences and chromosomal locations can be found 
at www.mlpa.com. 
All MS-MLPA reactions were done according to the manuf cturer’s instructions with 
minor modifications, using 100-150 ng of DNA. The probe-mix is added to 5ul of 
denatured DNA and allowed to hybridize for 16 hours at 60°C. Subsequently, the sample 
is divided in two: one half is ligated by adding 10ul of ligase-mix, whereas in the other 
half ligation is combined with digestion by adding 10ul of ligation-digestion mix. These 
sample are incubated for 30 minutes at 54°C, then t HhaI enzyme is inactivated by 
denaturation at 95°C for 1 minute. Since the unmethyla ed sequences are cut by the 
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Table 3: Genes examined by MS-MLPA analysis 
N° gene position ID number Amplicon size 
1 TP73 1p36.3 NM_005427.2 400*; 238** 
2 CASP8 2q33.2 NM_001228 265* 
3 VHL 3p25.3 NM_000551 355*; 265** 
4 RARB 3p24.2 NM_000965 193*; 454** 
5 MLH1 3p22.3 NM_000249 166*; 463* 
6 RASSF1 3p21.3 NM_007182 328*; 382* 
7 FHIT 3p14.2 NM_002012 409* 
8 APC 5q22 NM_000038 148* 
9 ESR1 6q25.1 NM_000125 373*; 301** 
10 PAX5A 9p13 NM_016734 211** 
11 CDKN2A (p14) 9p21.3 NM_058195 160* 
12 CDKN2A (p16) 9p21.3 NM_058195 427** 
13 DAPK1 9q22 NM_004938 346* 
14 PTEN 10q23.3 NM_000314 292*; 184** 
15 MGMT 10q26.3 NM_002412 193**; 382** 
16 CD44 11p12 NM_000610 319*; 463** 
17 GSTP1 11q13 NM_000852 454*; 274** 
18 PAX6 11p13 NM_001604 409** 
19 WT1 11p13 NM_000378 247** 
20 ATM 11q23 NM_000051 184*; 160** 
21 IGSF4 11q23 NM_014333 427*; 355** 
22 CDKN1B 12p13.2 NM_004064 274* 
23 CHFR 12q24.3 NM_001161344 238*; 292** 
24 BRCA2 13q13.1 NM_000059 301*; 148** 
25 RB1 13q14.2 NM_000321 319**; 472** 
26 THBS1 15q15 NM_003246 346** 
27 PYCARD 16p11.2 NM_013258 400** 
28 CDH13 16q23.3 NM_001257 436*; 220** 
29 TP53 17p13.1 NM_000546 166 
30 HIC1 17p13.3 NM_006497 220* 
31 BRCA1 17q21.3 NM_007294 247*; 142** 
32 STK11 19p13.3 NM_000455 373** 
33 GATA5 20q13.3 NM_080473 436** 
34 TIMP3 22q12.3 NM_000362 142* 
Legend: * ME001-C1 MS-MLPA kit; ** ME002-A1 MS-MLPA kit (MRC-Holland, The 
Netherlands). 
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restriction enzyme, this process resultes in the ligation of the methylated sequences only. 
Eight microlitre of the two aliquots are then amplified in a 25ul PCR reaction using Veriti 
thermo cycler (Applied Biosystems, Foster City, USA) with this thermal protocol: 33 
cycles of denaturation at 95°C for 20 s, annealing at 60°C for 30 s and extension at 72°C 
for 1 min with a final extension of 20 min at 72°C. In order to assess MS-MLPA 
reliability two replicates were performed for each sample and positive and negative 
controls using fully methylated DNA (CpGenome Universal Methylated DNA, Millipore) 
and unmethylated DNA (CpGenome Universal UnMethylated DNA, Millipore) were 
included in each MS-MLPA experiment. Aliquots of 1.5 ul of the PCR reaction were 
combined with 0.5 ul TAMRA internal size standard (Applied Biosystems, Foster City, 
USA) and 13.5ul of deionized formamide. After denatur ion, fragments were separated 
and quantified by electrophoresis on an ABI 310 capillary sequencer and Genemapper 
analysis v.4.0 (Applied Biosystems). Values corresponding to peak size (base pairs) and 
peak height were used for further data processing by Coffalyser V7 software (MRC-
Holland). Methylation dosage ratio (MR) was obtained by the following calculation: MR= 
(Px/Pctrl)Dig / (Px/Pctrl)Undig where Px is the peak height of a given probe, Pctrl is the sum of 
the peak heights of all control probes, Dig stands for HhaI digested sample, and Undig 
stands for undigested sample.  
A methylation ratio (MR) for a given gene may range from 0 (0% of alleles methylated) 
to 1.0 (100% of alleles methylated) and threshold values of 0.3 and 0.7 are suggested by 
the manufacturer to consider a locus as hemi-methylated or fully-methylated, respectively. 
However we determined in our laboratory sensitivity and specificity of each probe as well 
as the of accuracy MS-MLPA to provide semi-quantitative results by a titration 
experiment using mixtures of fully methylated DNA (CpGenome Universal Methylated 
DNA, Millipore) and unmethylated DNA (CpGenome Universal UnMethylated DNA, 
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Millipore). Serial dilutions of 0%, 10%, 30%, 50%, 80% and 100% of methylation were 
analysed three times resulting in three data points for each dilution. MRs obtained in the 
titration experiments were evaluated by Receiver Operating Characteristic (ROC) curve 
analysis 61,62. 
 
Validation of MS-MLPA results by methylation-specific PCR and by bisulphite 
pyrosequencing 
 
To validate the MS-MLPA results, we used methylation-specific PCR (MSP) 63 and 
bisulphite pyrosequencing 64 to analyse the same promoter regions interrogated by MS-
MLPA probes. MS-PCR was applied to analyse hMLH1 methylation status using 
previously published primers and protocol 65. All MSP data were obtained by capillary 
electrophoresis on an ABI 310 Automatic DNA Sequencer (Applied Biosystems, Foster 
City, CA). 
Bisulphite pyrosequencing was used to confirm methyla ion patterns of the MGMT gene. 
Bisulfite modification of genomic DNA (300 ng) was performed with an EpiTect Bisulfite 
Kit (Qiagen, Hilden, Germany) according to the manuf cturer’s recommendations. 
Bisulfite-modified DNA was amplified and sequenced by using primers supplied in a 
PyroMark MGMT kit (Diatech, Jesi, Italy). The biotinylated strand of each PCR product 
was isolated from 20 µl of each PCR product using a Vacuum Prep Tool (Qiagen). 
Pyrosequencing was carried out with PyroGold reagents o  a PyroMark Q96 ID system 
(Qiagen). Pyrogram outputs were analyzed by the Pyroma k Q24 software using the 
Allele Quantification software (Qiagen) to determine the percentage of methylated alleles 
at each of the four CpG sites examined. Aberrant methylation was scored when the mean 
value of the percentage of methylated alleles was higher than 15%. 
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Statistical analysis  
 
Univariate comparisons of continuous data were carried out using Student’s t-test and 
discrete variables were compared with χ2 test or Fisher’s exact test. The association 
between discrete outcome and continuous predictor was evaluated with a logistic 
regression model. All comparisons were two-sided and  p-value <0.05 was considered to 
be significant.  
The cut-off value of the methylation ratio (MR) of each gene with corresponding 
sensitivity, specificity and accuracy was estimated by Receiving Operator Characteristic 
curve analysis 61,62. The best statistical cut-off was calculated to achieve the highest levels 
of accuracy to detect at least 10% of methylation in each gene.  
Survival analysis was performed using Kaplan Meier curves, log-rank test and the Cox 








MS-MLPA quality assessment: evaluation of reproducibility and accuracy. 
Reproducibility of the MS-MLPA assay was assessed by performing in duplicate the 
analysis of 142 FFPE DNA samples, after checking the integrity and amplifiability by 
BIOMED-2 multiplex PCR generating products of 100, 2 0, 300, 400 and 600 bp. MS-
MLPA raw data were reproducible in all the 104 tumor samples (Table 2, materials and 
methods) and the 25 normal samples included in this study. All these DNA samples 
showed products of 200 bp or more in the multiplex PCR. By contrast, this analysis led to 
the exclusion of a total of 13 DNA samples (9% of cases). These cases, showing amplified 
products smaller than 200 bp, displayed discordant r w data between the two replicates. 
Representative MS-MLPA results with respect to DNA amplifiability are shown in figure 
5. 
Normal values for the 53 MS-MLPA probes included in the two kits were determined by 
testing normal controls from lymphocytes of healthy donors. Reproducible results with all 
the probes were found, with the exception of the probes 0607-L00591 (CDKN2B gene) 
and 01250-L00798 (MSH6 gene) which provided false positive results because of 
incomplete HhaI digestions. For this reason these two probes were not taken into account 
in the subsequent analyses. 
To further assess the robustness of the MS-MLPA assay, raw data derived from two 
different probes interrogating the same gene were compared for 17 of the 34 genes 
examined (Table 3). As illustrated in figure 6, high levels of concordance were observed 
by comparing the MR data obtained with the two probes for all 17 genes (average 
concordance: 91% ± 7.6). Only for MGMT probes we found a low level of concordance, 
equivalent to 55%. Thus, promoter methylation of MGMT gene was tested with a 
comparative analysis using pyrosequencing method (see “Validation of MS-MLPA results 
by MS-PCR and by pyrosequencing”).  
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Figure 5. Examples of MS-MLPA results with respect o amplifiability of DNA samples. 
A 3% agarose gel shows control genes PCR products of five DNA samples obtained from FFPE tissues. 
Electopherograms show replicates (R1 and R2) of MS-MLPA raw data from two representative DNA 
samples displaying an amplifiability of 300bp and 100bp (case 1 and case 5 respectively). As evident, 
sample 5 did not allow to obtain reproducible results.  
 
Accuracy of the MS-MLPA assay was evaluated through the assessment of sensitivity and 
specificity of the method performing ROC analysis on titration experiment data. The 
methylation status of the 34 genes under study was tested on dilutions of increasing 
percentages of in vitro methylated DNA and unmethylated DNA (0%, 10%, 30%, 50%, 
80% and 100%). As illustrated in Table 4, the MRs in the MS-MLPA analysis gradually 
increased with the degree of methylation. 
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Figure 6. Concordance levels between two probes interrogating the same gene.  
Percentage of concordance of results are displayed in y-axis. CONC, concordance; DISC, discordance. 
 
Sensitivity was 100% for all probes because no false negatives were observed. By 
contrast, specificity differed depending on the gene probe, ranging from 83% to 50%. In 
general, the titration experiment demonstrated that MS-MLPA analysis can discriminate, 
almost for all the probes, samples containing 10%, 30% and 50% methylated sequences 
while no distinction can be made among samples withmore than 50% of methylation. 
Moreover, some probes (see for example RASSF1) werenot able to discriminate between 
10% and higher levels of methylation. For all these motives, we scored aberrant 
methylation as a categorical variable. Furthermore as the application of an universal cut-
off (0.3 suggested by the manufacturer) for all the 34 probes to score absence or presence 
of methylation was not applicable indiscriminately to all probes due to the peculiar 
specificity of each probe, a specific MR threshold was calculated for each gene. These 
















































































Table 4: Results of the titration assay to assess linearity, sensitivity, specificity and accuracy of MS-MLPA  
MS-MLPA methylation-ratios  
in DNA mixing analysis 
ROC analysis results 
Genes 








TP73 0.06 0.21 0.42 0.73 0.84 0.94 0.32 95.8 83 100 
ESR1 0.06 0.27 0.56 0.92 1.00 0.88 0.42 95.8 83 100 
CDKN2A p16 0.06 0.21 0.49 0.82 0.95 1.00 0.24 95.8 83 100 
CDKN2A p14 0.06 0.16 0.46 0.74 0.95 1.00 0.36 95.8 83 100 
DAPK1 0.00 0.21 0.39 0.67 0.83 1.00 0.22 95.8 83 100 
ATM 0.00 0.16 0.38 0.65 0.85 0.92 0.26 95.8 83 100 
 IGSF4 0.05 0.23 0.47 0.82 0.92 0.89 0.35 95.8 83 100 
CDKN1B 0.03 0.19 0.36 0.67 0.85 0.97 0.25 95.8 83 100 
CHFR 0.00 0.20 0.46 0.78 0.99 0.99 0.34 95.8 83 100 
BRCA2 0.02 0.22 0.51 0.85 1.00 1.00 0.36 95.8 83 100 
THBS1 0.03 0.18 0.49 0.73 0.83 0.96 0.25 95.8 83 100 
TP53 0.04 0.14 0.43 0.70 0.82 0.89 0.21 95.8 83 100 
BRCA1 0.02 0.18 0.46 0.77 0.98 0.96 0.31 95.8 83 100 
GATA5 0.05 0.18 0.45 0.72 0.97 0.99 0.24 95.8 83 100 
TIMP3 0.00 0.19 0.38 0.67 0.91 0.95 0.28 95.8 83 100 
VHL 0.01 0.27 0.68 1.00 1.00 0.93 0.17 91.7 67 100 
MLH1 0.00 0.24 0.44 0.70 0.88 1.00 0.2 91.7 67 100 
FHIT 0.01 0.26 0.44 0.86 0.92 0.86 0.24 91.7 67 100 
APC 0.00 0.43 0.58 0.76 0.96 1.00 0.44 91.7 67 100 
PTEN 0.05 0.25 0.53 0.85 1.00 1.00 0.16 91.7 67 100 
MGMT 0.05 0.44 0.55 0.80 1.00 0.90 0.38 91.7 67 100 
CD44 0.01 0.65 0.99 1.00 1.00 0.85 0.66 91.7 67 100 
GSTP1 0.00 0.41 0.85 1.00 1.00 1.00 0.28 91.7 67 100 
PAX6 0.00 0.24 0.49 0.75 0.93 0.91 0.23 91.7 67 100 
WT1 0.10 0.33 0.53 0.83 0.94 0.89 0.31 91.7 67 100 
RB 0.03 0.29 0.69 1.00 1.00 1.00 0.2 91.7 67 100 
PYCARD 0.00 0.19 0.39 0.67 0.91 0.98 0.21 91.7 67 100 
CDH13 0.11 0.56 0.75 1.00 1.00 0.94 0.58 91.7 67 100 
HIC1 0.00 0.35 0.68 1.00 1.00 1.00 0.22 91.7 67 100 
STK11 0.02 0.35 0.84 1.00 1.00 1.00 0.23 91.7 67 100 
CASP8 0.01 0.56 0.68 0.82 0.88 0.99 0.41 87.5 50 100 
RARB 0.00 0.31 0.52 0.81 0.97 1.00 0.27 87.5 50 100 
RASSF1 0.00 0.81 0.79 0.94 0.98 1.00 0.57 87.5 50 100 
PAX5 0.00 0.32 0.55 0.74 0.94 0.90 0.3 87.5 50 100 
Legend: MR threshold: MS-MLPA ratio chosen to score aberrant methylation in each gene (>MR value). 
Based on ROC curve analyses these values correspond to the highest levels of accuracy to detect at least 
10% of methylation. 
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Validation of MS-MLPA results by MS-PCR and by pyrosequencing 
 
MS-MLPA was validated for methylation patterns in hMLH1 and MGMT genes by MSP 
and by PCR-pyrosequencing. As is evident from both comparative analyses reported in 
table 5, there was a very high correlation between MS-MLPA and the other two methods 
(p<10-14). In particular, MS-MLPA and pyrosequencing showed a concordance of results 
in 96% of tumor samples analyzed for MGMT methylation (92 out of 96 cases). Among 
the four discordant cases, 3 of the 96 samples (3%) were negative in the MS-MLPA 
analysis and showed a mean percentage of methylation in the five CpG dinucleotides of 
about 15-20% in the pyrosequencing analysis. On the contrary, one case was positive with 
the MS-MLPA method but negative with pyrosequencing. Comparing the MS-MLPA and 
MSP methods, there was agreement between the two appr aches in 95% of the samples 
(97 of 102 cases). All five discordant samples showed methylation of hMLH1 using MSP 
but were negative in the MS-MLPA analysis. 
 
Table 5: Validation of MS-MLPA results by methylation-specific PCR (MSP) and by bisulphite 
pyrosequencing 
 
Legend: MSP, Methylation-Specific PCR; +, methylated; -, unmethylated; +/+, positive for both; 
-/-, negative for both; +/-, positive MS-MLPA/negative pyrosequencing or MSP; -/+, negative 
MS-MLPA/ positive pyrosequencing or MSP. 
Genes MS-MLPA/PYROSEQUENCING P 
 +/+ -/- +/- -/+  
MGMT 25 (26%)  67 (70%) 3 (3%) 1 (1%) 10-17 
   
 MS-MLPA/MSP P 
 +/+ -/- +/- -/+  
MLH1 15 (15%) 82 (80%) 0 (0%) 5 (5%) 10-12 
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Overall frequencies for promoter methylation in normal colorectal mucosa and in 
CRC samples 
 
Methylation patterns of all 34 genes were examined by MS-MLPA in the 104 tumor 
samples, in adjacent mucosa of 13 CRC patients, as well as in colonic mucosa from 12 
patients without evidence of malignancies. The selection of these 25 normal samples was 
carried out in order to represent all colorectal segm nts; the median age of the patients 
was 70 years, without significant differences betwen the two groups. 
In order to exclude age related methylation, we correlated patient age (continuous 
variable) with methylation of each gene through the logistic regression model and we 
found a weak association between increasing age and presence of methylation of ESR1 
and of THBS1 genes (OR values: 1.07, C.I.: 1.002-1.14 , p=0.045 and 1.09, C.I.: 1.003-
1.205, p=0.043). For all the other genes, no associati ns were present. 
As reported in figure 7, a significant increase in the level of gene methylation is evident 
going from samples of normal mucosa of control cases to samples of normal mucosa of 




























Figure 7. Number of methylated genes in normal and tumor samples. The box plots describe the 
different frequencies of methylated genes in colorectal mucosa of non neoplastic patients (N*), in 
the normal mucosa of patients with CRC (N**) and in CRCs.  
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In the first group we did not observe gene methylation, with the sole exception of ESR1 
and STK11 genes that showed methylation in 3 and in 4 samples, respectively, as shown 
in detail in figure 8. Higher levels of methylation were detected in normal mucosa of 
CRC-patients and the following genes showed methylation: GATA5 (77%), RARB (38%), 
MGMT (31%), PYCARD (23%), WT1 (23%) PTEN (23%), ESR1 (15%).  
In the group of tumor samples ESR1, WT1 and GATA5 were methylated in more than 80% 
of cases. Intermediate levels of methylation between 10% and 45% were observed for the 
following genes: CDH13, CDKN2A (p16), RARB, MGMT, CHFR, PAX6, PAX5A, TIMP3, 
DAPK1, STK11, APC, hMLH1, PTEN, HIC1, IGSF4, and RB1. The remaining genes were 
rarely methylated, showing methylation in less than 10% of cases. 
 
MS-MLPA profiles for clinico-pathological and biological stratification of CRCs 
 
A subgroup of 27 colorectal cancers (26% of cases) howed extensive gene methylation 
involving more than 25% of the promoters examined. This finding suggested the presence 
of a CIMP+ phenotype in these samples (Figure 8). The methylation of the following 12 
genes was significantly correlated with CIMP+: RARB, hMLH1, CHFR, TIMP3, HIC1 
(p<0.0001), THBS1 (p=0.0007), PAX5A (p=0.003), MGMT (p=0.004), PAX6 (p=0.006), 
CDH13 (p=0.007), APC (p=0.01), and CDKN2A (p16) (p=0.04).  
The presence of CIMP was observed with similar frequency in exocrine CRCs and in 
NECs (25% versus 29%, respectively). Among the exocrine CRCs, CIMP+ was 
significantly associated with the presence of MSI (58% of MSI tumors versus 16% of 
MSS tumors). Among NECs, we observed MSI in two cases that also showed CIMP. 
Overall the presence of MSI was the marker most strongly associated with widespread 
methylation (p<0.0001). 
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We first assessed the clinico-pathological and biological characteristics significantly 
associated with CIMP considering all 27 CIMP+ tumors regardless of the MSI status. This 
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0,9 0,9 0,9 0,9
0,4 0,5 0,6 0,9 0,1 0,1 0,2 0,1 0,1 0,1 0,5 0 0 0,1 0,4 0,1 0,4 0,4 0,2 0,5 0,4 0,4 0,4 0,5 0,5 0,4
0,7 0,8 0,9 0,2 0,1 0,1 0,1 0,2 0 0,3 0,1 0 0,7 0,2 0,2 0,4 0,2 0,3 0,8 1 0,8 0,5 0,7 0,6 0,7 0,6
0,8 0,8 0,8 0,8 0,1 0,1 0,1 0,4 0,1 0,1 0,5 0 0,2 0,1 0,2 0,2 0,6 0,3 0,1 0,2 0,6 0,6 0,2 0,6 0,8 0,5
1 0,7 0,3 0,3 0,1 0,2 0,2 0,2 0,1 0,5 0,1 0 0 0,2 0,6 0,1 0,3 0,5 0,5 0,1 0,5 0,4 0,2 0,4 0,5 0,3
0,8 0,6 0,8 0,1 0,3 0,2 0,3 0,1 0,1 0,7 0,7 0 0,1 0,1 0,1 0 0,4 0,4 0,5 0,7 0,4 0,3 0,1 0,3 0,6 0,5
0,5 0,5 0,6 0,1 0,3 0,1 0,1 0,1 0 0 0,1 0 0 0,1 0,1 0,2 0,1 0,3 0,2 0,1 0,5 0,4 0,4 0 0,6 0,1
0,6 0,5 0,7 0,1 0,1 0,1 0,1 0,1 0 0,2 0,1 0,1 0 0,1 0,1 0,2 0,3 0,7 0,8 0,2 0,1 0,2 0,5 0,8 0,8 0,7
0,8 0,6 0,8 0,1 0,7 0,1 0,1 0,1 0 0,1 0,3 0,1 0,2 0,1 0,3 0,1 0,9 0,5 0,6 0,1 0,4 0,5 0,1 0,9 1
0,7 0,5 0,8 0,2 0,2 0,1 0 0,2 0,1 0,1 0 0,2 0,2 0,2 0,2 0,5 0,4 0,2 0,1 0,4 0,6 0,4 0,4 0,4 0,6 0,3
NV
0,5 0,7 0,3 0,2 0,2 0,1 0,1 0 0,1 0,7 0,1 0 0,1 0,2 0,3 0,2 0,8 0,5 0,1 0,5 0,4 0,3 0,3 0,4
0,6 0,5 0,5 0,3 0,1 0,1 0,2 0,1 0 0,1 0,1 0,1 0 0,1 0,2 0 0 0,3 0,7 0,7 0,3 0,3 0,9 0,6 0,9 0,3
0,6 0,9 0,7 0,2 0,3 0,2 0,3 0,2 0,2 0,3 0,1 0,1 0,3 0,2 0,2 0,5 0,2 0 0,2 0,3 0,6 0,4 0,5 0,1 0,2 0,6
0,7 0,6 1 0,8 0,9 0,2 0,2 0 0,2 0,3 0,5 0,2 0 0,2 0,1 0,2 0,2 0 0,2 0,2 0 0,3 0,6 0,1 0,7 0,3
0,8 0,5 0,7 0,3 0,8 0,2 0 0,1 0,1 0,3 0,5 0,3 0 0,1 0,2 0 0,1 0 0,1 0,3 0,3 0,5 0 0,5 0,8 0,3
0,8 0,7 0,5 0,3 0,3 0,2 0,9 0,2 0,1 0,1 0,1 1 0,1 0,2 0,6 0,1 0 0,2 0,2 0,4 0,5 0,1 0,9 0,8 0,1
0,6 0,5 0,7 0,8 0,2 0,2 0,4 0,2 0,1 0,2 0,3 0,1 0,2 0,2 0,3 0,1 0,1 0 0,3 0,1 0,1 0,3 0,2 0,3 0,9 0,3
0,8 0,8 0,9 0,7 0,1 0,1 0,1 0,1 0 0,1 0,2 0 0 0,1 0,4 0,6 0,1 0,3 0 0,1 0 0,4 0,6 0,4 0,4
0,6 0,8 1 0,1 0,1 0,1 0,1 0,5 0 0,1 0,5 0,1 0 0,1 0,2 0,5 0,1 0,8 0,2 0 0,5 0,4 0,1 0,3 0,3 0,7
1 0,8 0 0,1 0 0,1 0 0,4 0 0 0,2 0,4 0 0,1 0,2 0,1 0,1 0,1 0,1 0,1 0,7 0,6 0,1 0,2 0,4 0,3
0,8 0,5 1 0,2 0 0,3 0 0 0,2 0,3
NV
0 0,2 0,2 0 0,1 0,1 0,2 0 0,8 0,4
0,9 0,5 0,9 0,3
NV
0,1 0,1 0,1 0,1 0,1 0 0,1 0,2 0,3 0,2 0 0,2 0,2 0,4 0,3 0,4 0,3 0,6 0,3
0,6 0,4 0,4 0,2 0,3 0,3 0,5 0,4 0,7 0,8 0,3 0 0,4 0,3 0,2 0,4 0,1 0,5 0,4 0,3 0,1 0,2 0,5 0,1 0,6 0,4
0,7 0,6 0,5 0,1 0,4 0,2 0,3 0,4 0,2 0,2 0,5 0 0,1 0,1 0,1 0,3 0,1 0 0,1 0,2 0 0,2 0,7 0,4 0,8 0,7
0,8 0,9 0,5 0,1 0,4 0,2 0,3 0,1 0,4 0,8 0,2 0 0,1 0,1 0,2 0,2 0,1 0,1 0,2 0,1 0,1 0,6 0,1 0,4 0,8 0,7
0,6 0,7 0,7 0,1 0 0,1 0,1 0,3 0,1 0,2 0 0 0,5 0,1 0,3 1 0,2 0 0,2 0 0,1 0,8 0,9 0,2
0,9 0,8 0,9 0,2 0,1 0,1 0,1 0,1 0,8 0,1 0,8 0 0,1 0,2 0,1 0,4 0,2 0 0,4 0 0 0,1 0,3 0,7 0,8 0,4
NV
0,9 0,9 0,4 0,1 0,8 0 0,3 0,1 0 0 0 0 0,1 0,1 0,6 0 0 0,1 0 0 0,9 0 0,9 0,9 0,5
0,5 0,7 0,5 0,1 0,3 0,2 0,2 0,2 0,2 0,2 0,3 0,1 0,2 0,2 0,2 0 0,1 0 0,3 0,1 0,7 0,5 0,1 0,4 0,5 0,4
0,4 0,5 0,4 0,2 0,1 0,1 0,2 0,1 0,1 0,1 0,1 0,1 0 0,1 0,2 0,1 0,1 0 0,3 0,1 0,4 0,7 0 0,2 0,9 0,1
0,8 0,4 0,5 0,1 0,3 0,3 0,2 0,1 0,2 0,2 0,4 0,1 0,2 0,2 0,1 0,1 0,2 0 0,2 0,1 0 0,2 0,6 0,7 0,6 0,4
0,8 0,5 0,8 0,2 0 0,2 0,1 0,2 0,1 0,2 0,1 0,1 0 0,2 0,1 0,2 0,2 0,4 0,4 0,2 0,1 0,3 0,5 0,1 0,5 0,3
1 0,9 0,6 0,1 0 0,1 0,2 0 0,1 0 0,9 0,1 0 0,1 0,1 0,5 0,6 0 0,7 0,1 0 0,1 0,4 0,6 0,6 0,4
0,6 0,6 0,4 0,1 0 0,1 0 0,1 0 0 0,3 0 0 0,1 0,1 0,1 0,8 0,2 0,5 1 0,4 0,2 0 0,8 0,9 0,6
0,9 1 0,9 0,1 0 0,1 0 0,1 0,1 0 0 0 0 0,1 0,6 0,2 0,1 0,1 0,5 0,3 0,1 0,3 0,2 0,1 0,6 0,7
0,6 0,8 0,3 0,2 0 0,1 0 0,2 0 0,3 0,1 0,1 0,1 0,2 0,2 0,1 0,2 0,3 0,7 0 0,1 0,4 0,2 0,3 0,5 0,1
0,3 0,8 0,5 0,2 0 0,1 0,1 0,2 0 0 0,2 0,1 0 0,1 0,2 0,1 0,1 0 0,3 0,1 0,3 0,3 0,3 0 0,6 0,3
0,5 0,6 0,7 0,1 0,1 0,1 0,2 0,2 0,1 0,1 0,1 0,1 0,1 0,1 0,1 0 0,4 0 0,5 0 0,1 0,1 0 0 0,3 0,1
0,5 0,3 0 0,1 0,1 0,1 0,1 0,1 0 0 0,1 0,1 0 0,1 0 0,1 0,2 0 0,1 0,1 0 0,1 0,1 0,3 0,5 0,1
0,5 0,5 0 0,1 0 0,1 0,2 0,1 0 0,2 0,2 0 0 0,1 0,1 0 0,2 0,5 0,2 0 0,1 0,2 0,4 0,3 0,6 0,3
NV
0,6 0,6 0 0 0,1 0 0,1 0 0 0,1 0 0 0,1 0,1 0,1 0,1 0,3 0,3 0,1 0,2 0,3 0,1 0,1 0,4 0,1
0,7 0,5 0,3 0,9 0,2 0,2 0,2 0,1 0,1 0,1 0,1 0 0 0,1 0,1 0,2 0,3 1 0,4 0 0,2 0,3 0,3 0,6 0,1
0,5 0,5 0,9 0,2
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Figure 8. Methylation profiles of normal and tumor samples. Analytic description of presence 
of methylation (black cells) or absence of methylation (white cells) in each gene is illustrated for 
each sample. Genes whose methylation is associated with the CIMP+ phenotype are reported on 
the right side of the graph and are highlighted in bold. Gray cells are used for unavailable data. 
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colon (p=0.02), showed poor differentiation (p=0.05) and, among exocrine CRCs, 
mucinous histology (p=0.001) and histological heterog neity (p=0.02). CIMP+ tumors 
more frequently exhibited BRAF mutation (p=0.005) and the absence of loss of 
heterozygosity at 5q, 17p and 18q (p=0.008).  
However, figure 9 clearly emphasizes that all these features were typical of CIMP+ 
tumors with MSI and that the associations found betwe n CIMP and specific clinico-
pathological/molecular features were strongly influenced by MSI status. Indeed, when 
considering only the group of MSS tumors, the statiical significance of all associations 
reported above was lost. 
 
 
Figure 9. Distribution of clinico-pathological and molecular characteristics in MSI and MSS 
tumors with regard to CIMP+ and CIMP- phenotype.  
 
 
When considering CIMP status and cancer-specific survival, we observed a trend towards 












CIMP CIMP negative CIMP CIMP negative
MSI (n=21) MSS (n=83)
Right site







independent of MSI status because the presence of MSI was positively associated with an 
increased cancer-specific survival (p=0.04). Although not statistically significant because 
of the small number of cases, CIMP+ tumors with MSI were associated with a very good 
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Figure 10. Kaplan Meier survival analysis by CIMP status (panel A), by MSI status (panel B) 
and by the combination of both CIMP and MSI status (C). Log rank test was used to calculate p 
values for differences between groups. NS = p value not statistically significant. 
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Intriguingly, this result was observed also among NECs because the only two long 
surviving patients with NECs (alive with no evidenc of disease after 215 and 93 months, 
respectively) showed CIMP+ tumors with MSI. 
Specific methylation patterns of individual genes were observed comparing exocrine 
CRCs with NECs. In exocrine CRCs the most frequently methylated genes were 
CDKN2A (p16) and PAX6 (p<0.0001 and p=0.04, respectively). By contrast, methylation 








MS-MLPA is a new approach, described for the first time in 2005 51, that has mainly been 
applied in the study of genomic disorders associated with the loss of imprinting. So far, 
MS-MLPA has rarely been exploited in the analysis of gene methylation in tumors and 
very few studies about methylation profiling of CRCs using this method have been 
published 26,66.  
In this work we have optimized and successfully applied MS-MLPA analysis to an 
archival series of 104 CRCs and 25 normal colonic mu osa samples confirming that this 
method works very well with DNA from FFPE tissues providing highly reproducible 
methylation results. MS-MLPA is rapid and simple to perform, relatively inexpensive and 
allows screening for multiple predefined candidate genes simultaneously, using small 
quantities of input DNA. In addition, the assay can be performed in 96-well format, 
making it suitable for high throughput analysis and requiring only equipment widely 
available in molecular genetics laboratories. A particular strength of MS-MLPA is its 
ability to perform methylation analyses without labour intensive approaches based on 
sodium bisulphite treatment of the DNA. In this work we used two commercial MS-
MLPA kits and we demonstrated that methylation ratios for all but two probes under 
study were consistent and reproducible.  
A critical aspect of MS-MLPA is related to the use of a methylation-sensitive restriction 
enzyme to discriminate between methylated and unmethylated sequences. Incomplete 
digestion of unmethylated targets may lead to false-positive results and is a caveat 
inherent in most restriction enzyme-based methylation assays 67. However, this problem 
can be easily overcome by using at least two probes for each target sequence and 
introducing in each experiment positive and negative controls. Moreover it is possible to 
improve the application of the short-probe MS-MLPA approach, as recently described 68. 
The quality of DNA samples utilized in MS-MLPA reaction is another crucial question. 
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For all cases, we evaluated the reproducibility of replicates in the light of their 
amplifiability determined by control gene PCR, and we found a positive association 
between poor quality and low reproducibility, suggesting that DNA quality assessment is 
an important pre-requisite for MS-MLPA application. 
In our experience, another limitation of the assay i  that MS-MLPA is not a quantitative 
method to assess DNA methylation. Indeed, an important finding of our work is the 
demonstration that MS-MLPA shows a differential probe-to-probe capacity to 
discriminate among percentages of DNA methylation and that the highest values of 
accuracy are achieved defining aberrant methylation as a categorical variable by using 
specific cut-offs of MR for each gene. Moreover, the comparison of results obtained by 
two probes addressing the same promoter found concordance values higher than 77% for 
all probes, except for the one addressing MGMT promoter. However, subsequent 
validation tests of MGMT and MLH1 promoter methylation using pyrosequencing and 
MSP methods, confimed MS-MLPA results with an agreem nt of 96% and 95%, 
respectively. Overall these observations confirm that MS-MLPA may be considered an 
effective and simple first line tool to study DNA methylation in wide series of archival 
clinical samples. Importantly, the clinical translational application of this technology may 
also be related to the intrinsic flexibility of the MS-MLPA platforms and to the 
opportunity to develop targeted tumor-specific customized assays as well as to optimize a 
panel of “universal methylation markers” that could be useful in the analysis of gene 
methylation in different sites. 
Moreover, the employment of this technique, even using two commercial assays 
including predefined genes not specific to any tumor type, allowed us to reproduce 
findings that have been previously described by others using different methods 69-71 about 
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increased methylation in CRCs, the presence of CIMP in these tumours and its 
associations with specific clinico-pathological and molecular features. 
In the present work, we identified a total of 27 CIMP+ tumors consisting of 14 MSI 
cancers (12 exocrine CRCs and 2 NECs) and 13 MSS cancers (9 exocrine CRCs and 4 
NECs). Our result suggested that CIMP+ tumors with MSI represent a biologically and 
clinically distinct entity. In agreement with a large body of data in the literature 69-71, these 
tumors showed strong positive associations with proximal colon (92% of cases), poor 
differentiation (69% of cases), mucinous histology (73% of cases), histological 
heterogeneity (100% of cases), BRAF mutation (58% of cases) and absence of loss of 
heterozygosity at 5q, 17p and 18q (100%). 
Although all these associations remained significant when CIMP+ MSS cancers were 
added to the analysis, it was evident that this second subset of tumors was much more 
heterogeneous, showing the above mentioned features less frequently or not at all. 
Furthermore, the methylator phenotype lost it  prognostic meaning when we considered 
survival probability in stable tumors.  
On the other hand, in unstable tumors CIMP phenotype seems to select a subset of cases 
with a very good prognosis. Intriguingly, this result was observed also among NECs 
because the only two long surviving patients (alive with no evidence of disease after 215 
and 93 months) showed CIMP+ tumors with MSI. However, this hypotesis could not be 
definitively determined in our study because of thesmall number of cases and needs 
further investigations.  
NEC tumors are  rare and highly malignant cancers, most often located in the right colon 
and known to be associated with chromosomal instability and p53 alterations and, to date, 
very few works dealing with the role of aberrant methylation in these tumor entity have 
been published. In this work we demonstrated that DNA methylation as well as CIMP are 
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present in sporadic CRCs and in NECs with very similar frequencies. The observation that 
gene hypermethylation is a common feature of such different tumors supports the 
hypothesis that epigenetic abnormalities can characterize the earliest steps of tumors 
destined to progress differently. On the other hand, if the disruption of epigenetic 
machinery in the earliest phases of carcinogenesis seems to be a process common in the 
two tumor types, the presence of a gene-specific signature in these two entities suggests 
the involvement of aberrant methylation also in later steps, in association with sequence 
variations, thus determining the biologic fate of dif erent tumour types.  
Indeed, our study identified two different mehtylation pattern in exocrine and 
neuroendocrine tumors. Specifically, RASSF1, CASP8 and APC were more frequently 
methylated in NECs than in exocrine CRCs. These findings are consistent with previous 
studies reporting high frequencies of RASSF1 methylation in neuroendocrine tumors of 
the gastroentero-pancreatic system 36,72 and high frequencies of APC methylation in 
colorectal NECs 36. Similarly to our data for the colorectal site, unique profiles for gene 
methylation have been generated that can distinguish between non small cell lung cancer 
and small cell lung cancer 73,74. Intriguingly, small cell lung cancers that show clini o-
pathological features indistinguishable from those of NECs of various sites exhibit 
significantly higher frequencies of CASP8 and RASSF1 methylation compared with non 
small cell lung cancers 75. On the contrary, exocrine CRCs were characterized by high 
levels of methylation in CDKN2A/p16 and PAX6 promoters. Moreover, exocrine 
unstable tumours exhibited, as reported in many works 17, a specific profile of methylation 
including hMLH1, CDKN2A/p16, RARB, HIC1, PAX5A, PAX6, TIMP3 and CHFR genes. 
MS-MLPA analysis was performed also on 25 colorectal histologically normal mucosae. 
The comparison between methylated genes in normal coloni  tissues of 12 non-CRC 
patients versus 13 patients with CRCs included in th s study allowed us to identify a 
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“cancer-type methylation” in the last group of samples, as aberrant methylation was 
absent in the control group. Specifically, in histologically normal tissues of patients with 
CRC, methylation occurred in many genes, while only ESR1 and STK11 were methylated 
in mucosae of non neoplastic patients. We also checked whether the aberrant gene-
specific methylation in tumor-adjacent normal tissue  were found in matched tumours but 
we did not find the same pattern (data not shown). According to this observation, Belshaw 
and co-workers 76 recently demonstrated that variation in methylation levels existed 
between crypts from the same biopsy suggesting that human crypts are prone to random 
acquisition of aberrant gene methylation. 
An important finding of our work was the observation that some genes, found 
hypermethylated with high frequencies in cancers, ae also methylated in most of the 
colonic mucosae of CRC patients. Among these genes, GATA5 showed extensive 
methylation in a considerable number of tumour samples and it has been widely observed 
in normal mucosa of patients bearing CRCs (77% of cases) and never in the control 
group. Indeed, recent studies have highlighted the pot ntial diagnostic value of GATA4/5 
methylation for early detection and risk assessment of colon cancer 77,78.  Our analysis 
has also pointed out the potential usefulness of WT1 gene as an early diagnostic marker 
because of the very high frequencies of methylation in the present series. To date, a 
widespread methylation of this gene has been reportd in colorectal cancer, although very 
few studies have been published on this issue 79,80. In our opinion, this finding deserves to 
be further explored, especially with respect to thedisruption of methylation patterns 
described in CRCs to occur in 11p15 where WT1 maps together with IGF2, a known 
target of LOI events 10,81,82.  
Taken together, these data have important clinical and scientific implications suggesting 
the involvement of these genes in tumour initiation and proposing them as markers of 
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early neoplastic phases. Promoter methylation analysis of serum and stools DNA has 
recently been described as a potential tool to be used as a non-invasive test for the early 
diagnosis of CRC 78,83,84.  
In conclusion, our experience indicates that the MS- LPA assay is an easy and reliable 
system for epigenetic characterization of tumor tissues and presents innovative aspects 
that may have important scientific and clinical implications. 
Aberrant gene methylation is a common abnormality in CRC and may be observed in 
tumors with very different genetic and clinico-pathological profiles. The use of DNA 
methylation alterations as a molecular marker system could potentially be a powerful 
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